Trisomy X (Triple X) syndrome occurs at a frequency of approximately 1 in 1000 newborn females. The syndrome is associated with an increased risk of seizures and may affect short-term memory and learning although the majority of women affected show few clinical symptoms. AcceGen has developed iPSC-derived neural stem cells from a patient with the triple X chromosomal abnormality. All of the iPS cells examined (20 individual cells karyotyped), had trisomy X.AcceGen Human iPSC-Derived Neural Stem Cells (NSCs) are derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined neural induction conditions. The NSCs express typical markers of cerebral cortical neural stem and progenitor cells such as PAX6, FOXG1 and nestin, and spontaneously form polarized neural tube-like rosette structures when plated as a monolayer in culture (see below). Additionally, AcceGen NSCs are capable of generating a spectrum of cerebral cortical excitatory and inhibitory neurons that are electrically active and have the ability to form functional synapses and circuits in vitro. After thawing and plating, the neural stem cells terminally differentiate to acquire mature electrophysiological properties, and form functional synaptic networks over a period of 40 ~ 50 days.
AcceGen NSCs are easy to differentiate to neurons or mixed neural cell types, following our protocols and using our tailored media and reagent bundles. A highly pure population of neurons can be generated from AcceGen NSCs following the synchronous differentiation protocol. Using our specialized coating reagents, neurons derived from AcceGen NSCs can be maintained in culture long-term (>1 year). NSCs are available from multiple donors to suit your research needs and have been characterized extensively.
